Harvey I Cantor

US Patent:

6472170, Oct 29, 2002

Filed:

Jul 23, 1997

Appl. No.:

08/899367

Inventors:

Xiao-Feng Yang - Brookline MA
Georg F. Weber - Chestnut Hill MA
Harvey Cantor - Belmont MA

Assignee:

Dana-Farber Cancer Institute - Boston MA

International Classification:

C12N 1512

US Classification:

435 691, 536 234, 536 235, 4353201, 4352523, 43525411, 435325, 435410

Abstract:

The present invention relates to BCL-x, a novel isoform of the BCL-x family of proteins which is predominantly expressed in T-lymphocytes and is associated with resistance to apoptosis. Both compositions of matter and methods are described which are useful in the treatment or prevention of immune system disorders.

US Patent:

7160986, Jan 9, 2007

Filed:

Jul 29, 2002

Appl. No.:

10/208155

Inventors:

Xiao-Feng Yang - Brookline MA, US
Georg F. Weber - Chestnut Hill MA, US
Harvey Cantor - Belmont MA, US

Assignee:

Dana-Farber Cancer Institute, Inc. - Boston MA

International Classification:

C07K 14/47

US Classification:

530350, 435 691, 435 697

Abstract:

The present invention relates to BCL-xγ, a novel isoform of the BCL-x family of proteins which is predominantly expressed in T-lymphocytes and is associated with resistance to apoptosis. Both compositions of matter and methods are described which are useful in the treatment or prevention of immune system disorders.

US Patent:

8197817, Jun 12, 2012

Filed:

Dec 16, 2005

Appl. No.:

11/792790

Inventors:

Harvey Cantor - Wellesley MA, US
Nami McCarty - Houston TX, US

Assignee:

Dana-Farber Cancer Institute, Inc. - Boston MA

International Classification:

A61K 39/00
C12N 5/02
G01N 33/567

US Classification:

4241841, 435375, 435 721

Abstract:

The invention relates to compositions and methods used to assess and alter the expression and activity of MINK in cells of the immune system, particularly thymocytes and T lymphocytes. The methods and compositions are used in a variety of clinical applications including vaccination, treatment of cancer, infectious disease, allergy, and transplantation. Screening methods are provided to identify inhibitors of MINK and susceptibility to effects of under- or over-expression of MINK.

US Patent:

20130302276, Nov 14, 2013

Filed:

Oct 18, 2011

Appl. No.:

13/878894

Inventors:

Harvey Cantor - Wellesley MA, US
Hye-Jung Kim - Brookline MA, US
Linrong Lu - Hangzhou MA, US

Assignee:

DANA-FARBER CANCER INSITUTE INC., - BOSTON MA

International Classification:

A61K 35/14

US Classification:

424 852, 4241581, 424 9371, 435325, 4241841

Abstract:

A method to treat an autoimmune disease is provided. The method involves administration of interleukin-15 receptor (IL-15R) agonists in an amount effective to ameliorate a symptom of the autoimmune disease. The invention also involves a method to treat an autoimmune disease by ex-vivo expansion of CD44+CD122+Kir+ CD8+ Treg cells and administration of the CD44+CD122+Kir+ CD8+ Treg cells. Compositions comprising CD44+CD122+Kir+ CD8+ Treg cells are also provided. Methods for stimulating an immune response to an antigen are also provided.

US Patent:

52388395, Aug 24, 1993

Filed:

Jul 18, 1991

Appl. No.:

7/732185

Inventors:

Harvey I. Cantor - Wellesley MA
Roberto Patarca - Brookline MA
Joel L. Schwartz - Newton Centre MA
Gordon Freeman - Brookline MA

Assignee:

Dana Farber Cancer Institute - Boston MA

International Classification:

C12N 510
C12N 121
C12N 1519

US Classification:

4352401

Abstract:

The present invention relates to genes and their encoded proteins which induce immunological effector cell activation and chemattraction. The proteins of the invention attract subsets of immunological effector cells and stimulate them to express their specialized effector cell functions. Such proteins, termed Ap-1 proteins, are expressed by lymphoid cells, and bind to effector cells such as macrophages and mast cells. In particular, the Ap Pursuant to the provisions of 35 U. S. C. . sctn. 202(c), it is hereby acknoledged that the Governament has certain rights in this invention, which was made in part with funds from the National Institutes of Health.

US Patent:

46134590, Sep 23, 1986

Filed:

Oct 20, 1982

Appl. No.:

6/435510

Inventors:

Harvey I. Cantor - Boston MA
Gary Nabel - Cambridge MA

Assignee:

Dana-Farber Cancer Institute - Boston MA

International Classification:

C07K 328
C12N 500
C12N 502
C12N 138

US Classification:

530351

Abstract:

A family of growth factors, methods of making and using such growth factors in in vivo treatment of living mammalian cells, and products incorporating such growth factors, are disclosed. The growth factors were isolated from the supernatant fluid obtained by incubation of inducer T-cells in the presence of a suitable antigen or mitogen. The growth factors disclosed include a 14 Kd polypeptide which stimulates growth of both T-cells and B-cells, a 50 Kd polypeptide which stimulates B-cells to multiply and secrete immunoglobulins, and a 45 Kd growth factor which stimulates secretion of immunoglobulins by B-cells and stimulates rapid growth of certain mast cells, stem cells and certain other types of cells.

US Patent:

45593108, Dec 17, 1985

Filed:

May 20, 1983

Appl. No.:

6/496543

Inventors:

Harvey I. Cantor - Boston MA
Gary Nabel - Cambridge MA

Assignee:

Dana Farber Cancer Institute - Boston MA

International Classification:

G01N 3354
C12Q 129

US Classification:

436519

Abstract:

The present invention is directed to an in vitro assay, useful in determining the effectiveness of anti-allergy compounds and/or useful in measuring the degree of sensitivity of a patient to particular allergens. The present invention permits potential anti-allergy agents to be assayed in a number of ways. For example, the binding and dissociation rates of IgE to the mast cells in the presence and the absence of the substance being tested may be measured thereby giving a direct indication of that substance's ability to interfere with the IgE binding reaction. Another measure of a substance's potential as an anti-allergy agent is based upon the release of mediators or other compounds from the mast cells after sensitization by the allergen and exposure of the sensitized cells to the allergen. The present invention generally involves the following steps: (a) sensitizing cloned mast cells to an allergen; (b) exposing sensitized mast cells to the allergen in the presence of a test anti-allergy agent; and (c) measuring the reaction products of step (b) for an indication of test compound effect.

US Patent:

49524992, Aug 28, 1990

Filed:

Feb 11, 1988

Appl. No.:

7/154758

Inventors:

Harvey I. Cantor - Wellesley MA
Roberto Patarca - Brookline MA

Assignee:

Dana-Farber Cancer Institute - Boston MA

International Classification:

C12P 2100
C12P 2102
C12P 1934
C12N 1500

US Classification:

4351723

Abstract:

The present invention is directed to genes, termed Rpt-1 (regulatory protein T lymphocyte-1), which are expressed at higher levels by resting CD4. sup. + helper/inducer T cells relative to activated CD4. sup. + cells. The invention also relates to the proteins encoded by such genes, termed rpt-1 proteins, which regulate gene expression directed by the promoter region of the interleukin-2 receptor (IL-2r) alpha chain gene or by the promoter region of the long terminal repeat of human lymphotropic retroviruses such as the human immunodeficiency virus type 1 (HIV-1) human T cell leukemia virus (HTLV)-I, and HTLV-II. In particular, rpt-1 proteins down-regulate gene expression controlled by the promoter of the IL-2r alpha chain gene or by the promoter of the long terminal repeat of HIV-1. The proteins and nucleic acids of the invention have value in diagnosis and therapy of immune disorders such as AIDS. In a specific example of the present invention, an Rpt-1 gene and its encoded intracellular protein of approximately 41,000 daltons molecular weight are described.